


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on August 27, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121  
Examining Group 1644  
Patent Application  
Docket No. ARS-120  
Serial No. 10/565,741

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Maher M. Haddad, Ph.D.  
Art Unit : 1644  
Applicant : Yolande Chvatchko  
Serial No. : 10/565,741  
Filed : January 23, 2006  
Conf. No. : 2192  
For : Use of Soluble CD164 in Inflammatory and/or Autoimmune Disorders

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121 AND  
SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

In response to the written Restriction Requirement dated July 25, 2007 in the above-identified patent application, Applicant hereby elects to prosecute the invention of Group I (claims 24-42), without traverse. As the species, Applicant elects SEQ ID NO: 1. As the single specific inflammatory/autoimmune disease, Applicant elects multiple sclerosis.

Prior to examination, Applicant respectfully requests that the subject application be amended as follows: